Labcorp appoints Thomas Pike to lead Drug Development unit; will become CEO of spin-off company

LABCORP HOLDINGS INC.

Thomas Pike appointed President and CEO of Drug Development Clinical Development business, effective Jan 9, 2023.
Upon planned spin-off (expected mid-2023), Pike will become CEO and Chairman of the independent publicly listed company.
Paul Kirchgraber, current EVP and CEO of Drug Development, will depart after the spin-off; he continues leading Early Development, Central Laboratories, and Global Oncology.
Labcorp to announce the new company's Board of Directors, including lead independent director, in coming months.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas Pike

President and Chief Executive Officer of Drug Development Clinical Development business unit

LH · LABCORP HOLDINGS INC.

Effective: 2023-01-09
Filed: January 5, 2023, 6:59 PM ET

Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023

Departed

Paul Kirchgraber

EVP and CEO of Drug Development business segment

LH · LABCORP HOLDINGS INC.

Filed: January 5, 2023, 6:59 PM ET

Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Pike was appointed as President and Chief Executive Officer of Drug Development Clinical Development business unit at LABCORP HOLDINGS INC..

Action: appointed
Role: President and Chief Executive Officer of Drug Development Clinical Development business unit

Exact text from the filing

Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Kirchgraber departed as EVP and CEO of Drug Development business segment at LABCORP HOLDINGS INC..

Action: intends to depart
Role: EVP and CEO of Drug Development business segment

Exact text from the filing

Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.

View on SEC.gov

LABCORP HOLDINGS INC. filing history →

Source: SEC EDGAR

accession 0000920148-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.